Trial Profile
Single-Ascending Dose, Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of LY2886721 in Healthy Subjects.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs LY 2886721 (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions; Biomarker
- Sponsors Eli Lilly and Company
- 19 Jul 2012 Results presented at the 2012 International Conference on Alzheimer's Disease.
- 25 Nov 2010 Status changed from recruiting to completed.
- 14 Jun 2010 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.